Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

ReGeneraTing Agent (RGTA) for treatment of persistent epithelial defects

Poster Details

First Author: N.Solmaz TURKEY

Co Author(s):    G. Koca   F. Onder           

Abstract Details


To present the succesfull application of ReGeneraTing Agent (RGTA; Cacicol20, Paris, France), also called matrix therapy, for the treatment of persistent epithelial defect (PED).


Department of Ophthalmology, Haseki Training and Research Hospital, Istanbul, Turkey.


A 69-year old female patient with pseudophakic bullous keratopathy underwent penetrating keratoplasty (PK). In the early postoperative period, PED of 3.5 mm (width) x 3.0 mm (height) formed on the graft. The dimension of the PED did not decrease during the 4-weeks standart therapy period including the use of preservative-free topical medications, aggressive lubrication, pressure patching, 30% autologous serum and lastly temporary tarsorrhaphy. Since the PED was resistant to conventional treatment, the autologous serum use was discontinued and matrix therapy was started with one drop of Cacicol 20 every other day.


The PED started to shrink in the first week of matrix therapy. On the 20th day, the PED size had significantly decreased to 2.8 mm(width) x 1.2 mm (height). The tarsorrhaphy was opened and Cacicol20 treatment was combined with silicone hydrogel bandage contact lens (BCL) application. The PED were completely healed in one week. No adverse side effects were observed during the therapy. There was no recurrence during the 3-month follow up.


RGTA , which stimulates tissue regeneration by imitating the functions of extracellular matrix components, seems to be an effective therapeutic agent for PED resistant to conventional theraphy. However, prospective randomised clinical trials are needed to be able to better assess the effectiveness and the safety of the treatment.

Financial Disclosure:


Back to Poster listing